ArticleESMO gastrointestinal oncology2024

Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer.

Z A Wainberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.